FIELD: medicine.
SUBSTANCE: method involves administering xenon when neurointoxication is caused by neuromediators available in excess. Xenon reduces neuromediator release, first of all dopamine release, caused for instance by hypoxia conditions like apoplexy or craniocerebral injury. Xenon-containing composition is applicable as therapeutic agent for treating the cases of depression, schizophrenia and Parkinson disease distinguished by neuromediator equilibrium disorder. Inhalation introduction method is simple. Xenon is proved to be harmless while known to be useable as anesthetic means.
EFFECT: wider set of preparations usable for treating neurointoxication.
17 cl, 2 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION FOR INHIBITING NEURONAL APOPTOSIS OR NEURODEGENERATION | 2011 |
|
RU2586772C2 |
| METHOD FOR TREATING METASTATIC CEREBRAL AFFECTION | 2015 |
|
RU2599195C1 |
| PHARMACEUTICAL COMPOSITION FOR INHIBITING APOPTOSIS OF NEURONS OR NEURODEGENERATION | 2011 |
|
RU2722018C2 |
| METHODS OF NEURAL DISORDER TREATMENT WITH USING HEMATOPOIETIC GROWTH FACTORS | 2003 |
|
RU2353385C2 |
| METHOD FOR INCREASING THE LEVEL OF CONSCIOUSNESS OF PATIENTS WITH PROLONGED IMPAIRMENT OF CONSCIOUSNESS AFTER TRAUMATIC BRAIN INJURY | 2022 |
|
RU2789004C1 |
| NOVEL APPLICATION OF LIGNAN COMPOUNDS | 2006 |
|
RU2354370C1 |
| PRODUCTION OF GABA-ergic NEURONS in vitro OF EMBRYO STEM CELLS AND APPLICATION THEREOF IN TREATING NEURAL DISORDERS | 2004 |
|
RU2380410C2 |
| METHOD AND SYSTEM FOR APPLYING VARIABLE LOAD TO HUMAN BODY | 1997 |
|
RU2206307C2 |
| RASAGILINE COMPOSITIONS WITH PROLONGED RELEASE AND USE THEREOF | 2011 |
|
RU2734632C2 |
| CHROMON OXIME NEW DERIVATIVE AND ITS USE AS ALLOSTERIC MODULATOR OF METABOTROPIC GLUTAMATE RECEPTORS | 2015 |
|
RU2672569C2 |
